secwatch.observer — SEC 8-K summary
======================================

Issuer:     JOHNSON & JOHNSON (JNJ)
CIK:        0000200406
Form:       8-K
Filed at:   2026-07-15T11:49:04+00:00
Accession:  0000200406-26-000146
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

JNJ Q2 2026 revenue up 6.6% to $25.3B; adjusted EPS $2.90 (+4.7%)
-----------------------------------------------------------------

- Q2 sales $25,310M (+6.6% operational, +1.0% currency); GAAP net earnings $5,534M (-0.1%).
- GAAP diluted EPS $2.27 (-0.9%); adjusted diluted EPS $2.90 (+4.7%).
- Innovative Medicine sales $16,384M (+7.8%); MedTech $8,926M (+4.5%).
- US sales $14,533M (+7.3%); International $10,777M (+5.7%).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/200406/000020040626000146/0000200406-26-000146-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/200406/000020040626000146/jnj-20260715.htm
  HTML page:      https://secwatch.observer/filing/0000200406-26-000146

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer